LENZ Therapeutics, Inc.
LENZHealthcareNASDAQBiotechnology · Last scanned May 29, 2026
Scan Results
Daily timeframe1 of 4 indicators bullish as of May 28
Headquartered within the healthcare sector, LENZ Therapeutics, Inc. focuses on Biotechnology services and products. LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. The company carries a $250.5M market cap, placing it firmly in the micro-cap category. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults.
Market Cap
$250.5M
Beta
1.67
P/E (TTM)
—
P/E (Fwd)
-2.30
EPS (TTM)
$-3.64
EPS (Fwd)
$-3.47
ROE
-49.7%
ROA
-31.2%
Cash
$258.4M
Total Debt
$673,000
Free CF
-$48.8M
52W Change
-72.6%
Annual Financials
Cash vs Debt
LENZ Therapeutics, Inc. holds $258.4M in cash against $673K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$48.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -49.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
A beta of 1.67 means LENZ is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing LENZ's risk profile alongside its fundamentals and technical indicators provides a more complete picture.